Wegovy-maker Novo to invest €2.1bn in France to boost weight loss and diabetes drugs

The frenzy around the drugs, endorsed by celebrities and entrepreneurs including Elon Musk, turned Novo into Europe’s most valuable company.

Novo Nordisk plans to invest €2.1bn to expand production in France as it works to meet surging demand for its sought-after weight-loss medicines.

The construction work to beef up the Danish company’s site in Chartres, southwest of Paris, has already started, Novo said. The investment will increase capacity for the diet drug Wegovy and its sister product for diabetes, called Ozempic.